Bronchogen: Evidence, Mechanism, Dosing & Legal Status

Bronchogen is a synthetic tetrapeptide from Vladimir Khavinson's St. Petersburg 'bioregulator' program, proposed as a lung- and bronchial-tissue-specific gene-expression modulator.1 It is promoted in longevity and respiratory-recovery circles as an organ-specific peptide for the aging lung; its proof in humans is nonexistent. This monograph separates the mechanistic biology from the clinical claims.

This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing guide. Bronchogen is not an FDA-approved drug; it is sold as a "research chemical not for human use" and is plausibly prohibited in sport. Dosing figures are reported strictly as seen in the published literature for completeness — not as recommendations. Consult a licensed clinician before any health decision.

What is Bronchogen and how is it proposed to work?

Bronchogen is an ultrashort, four-residue peptide said to be modeled on peptide fragments isolated from bronchial mucosa, with molecular formula C18H30N4O9 and a molecular weight of roughly 446.5.1 Its sequence is reported inconsistently across the literature: most primary papers and the original DNA work specify Ala-Asp-Glu-Leu (ADEL), while commercial vendors and some later methylation papers list Ala-Glu-Asp-Leu (AEDL) — a transposed aspartate/glutamate order denoting the same product.34 When even the originating literature disagrees on residue order, precise specificity claims deserve scrutiny.

The proposed mechanism is unusual and not established in mainstream molecular biology. Unlike growth-factor or hormone-mimetic peptides, the Khavinson model holds that these di- to tetrapeptides enter cells and the nucleus and act as epigenetic regulators by binding DNA and histones directly, with no classical membrane receptor.1 Spectrophotometry, viscometry and circular dichroism indicated ADEL binds double-stranded DNA in the major groove at the N7 of guanine.1 An earlier biophysical study reported the peptide alters DNA melting and thermostability.3 In a tobacco model, 10⁻⁷ M AEDL reduced condensed-chromatin domains from roughly 45% to 25% of nuclear area, interpreted as decondensation toward transcriptionally active euchromatin via histone interaction.4 A follow-up reported preferential binding at the CTG methylation site, proposed to gate DNA-methyltransferase access.5 No formal human pharmacokinetic dataset — Cmax, half-life, clearance, bioavailability — has ever been published; oral dosing rests on a class-level claim that 2-to-4-residue peptides are partly absorbed via the intestinal transporters PEPT1 and PEPT2.6

What is the evidence by indication?

There are no human randomized controlled trials, no registered ClinicalTrials.gov entries with results, and no indexed cohort or observational efficacy studies for Bronchogen. All efficacy evidence is preclinical — rat in vivo plus human and plant cell systems — and nearly all of it originates from one Russian research lineage without independent Western replication. Every indication below is graded accordingly.

The strongest single study modeled COPD in rats by 60 days of intermittent NO₂ exposure; one month of Bronchogen therapy reversed hallmark remodeling — goblet-cell hyperplasia, squamous metaplasia, lymphocytic infiltration and emphysema — and restored ciliated cells, increased secretory IgA, and normalized bronchoalveolar lavage cell composition and pro-inflammatory cytokines.2 This is a rodent histopathology study with no functional pulmonary outcomes, no human data, and a single lab — animal-only, Grade C, not to be extrapolated to human COPD efficacy. In human embryonic bronchial-epithelial cultures across early and late passages, ADEL modulated proliferation and apoptosis proteins (Ki67, Mcl-1, p53) — with the strongest pro-proliferative effect in late-passage 'old' cultures — and up-regulated differentiation genes NKX2-1, SCGB1A1, SCGB3A2, FOXA1, FOXA2 plus MUC and SFTPA1.1 The 'geroprotective lung' framing is the authors' interpretation of cell-culture senescence, not demonstrated benefit in elderly humans.

What doses appear in the literature?

Reported strictly as information, not a protocol. No regimen below has been validated in a controlled human trial or sanctioned by any drug regulator, and there is no established human dose-response, no maximum tolerated dose, and no titration data.6 The Khavinson bioregulator convention is short pulsed courses of roughly 10 to 20 days, repeated one to two times per year, rather than continuous daily dosing.6 Oral 'Cytomax/Cytogen' capsule forms are taken once daily on an empty stomach during a course, with oral doses set higher than injectable to compensate for limited absorption; a frequently quoted vendor figure is about 200 micrograms per day orally — vendor-sourced, not trial-validated.6 An injectable research-chemical form is sold as a lyophilized powder (commonly 20 mg vials) labeled 'research use only,' reconstituted with bacteriostatic or sterile water; no sterility, potency, or endotoxin assurance applies to research-grade material.10 Russian respiratory practice describes pairing Bronchogen with Chonluten (Glu-Asp-Gly) for bronchopulmonary support.6

How safe is Bronchogen?

Human safety data are essentially none: no controlled human trials means no adverse-event tables, no laboratory-monitoring data, and no long-term safety profile exist, so claims of an 'excellent safety profile' are extrapolated from low-dose animal and cell work and class reputation, not demonstrated in humans.1 There is a theoretical mechanistic concern: any agent that drives epithelial proliferation (Ki67, Mcl-1) and alters DNA-methylation gating warrants caution in the setting of active or prior malignancy until properly studied — a first-principles caution, not an observed harm.5 Drug interactions are unstudied. The dominant real-world hazard is product quality: material sold as a research chemical, frequently injectable, carries no FDA assurance of identity, purity, sterility, or endotoxin limits, and the FDA has issued warning letters to facilities marketing such peptides for human use.10 Pregnancy, lactation, children, and active malignancy are precautionary contraindications.

What is the FDA and WADA status in 2026?

Bronchogen has no FDA approval — no NDA or BLA, no recognized therapeutic indication, and it is not a dietary-supplement-eligible ingredient for disease claims. It is marketed under the 'research use only, not for human consumption' framing and sits outside both the 503A compounding-pharmacy and 503B outsourcing-facility pathways; the broader 2024-2026 peptide-compounding tightening — bulk-substance review and warning letters — reinforces that such research peptides are not lawful for human compounding or administration.1011 It is not a DEA controlled substance. In Russia and Eastern Europe, Khavinson bioregulators are distributed as registered food supplements or parapharmaceuticals, which is not equivalent to FDA or EMA drug approval.6

For athletes the relevant fact is regulatory rather than evidentiary. Bronchogen is not explicitly named on the 2026 WADA Prohibited List, which came into force on 1 January 2026.8 However, category S0 (Non-Approved Substances) prohibits, at all times, any pharmacological substance not approved by any governmental health authority for human therapeutic use.9 As an unapproved research chemical, Bronchogen plausibly falls under S0, so any WADA-tested athlete or military service member should treat it as prohibited and consult their anti-doping authority.

Bottom line. Bronchogen pairs mechanistically interesting biology with a near-total absence of human proof. The honest evidence ceiling is Grade C: it reversed bronchial remodeling in a rat NO₂-COPD model and altered differentiation-gene expression while binding DNA in human cell cultures, but what is proven in humans is nothing — no RCTs, no cohorts, no registered trials, and the entire base traces to one Russian research group whose direct peptide-to-DNA mechanism remains independently unreplicated. Add a sequence-reporting inconsistency (ADEL vs AEDL), an unapproved research-chemical legal status, a likely WADA S0 prohibition, and the sterility and identity risks of gray-market injectables, and the responsible read is: promising preclinical biology, zero human efficacy or safety validation.